{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:35:24Z","timestamp":1772778924269,"version":"3.50.1"},"reference-count":12,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,6,29]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>The anti-PD-1 antibody cemiplimab has demonstrated effectiveness in the setting of locally advanced basal cell carcinoma (BCC) and squamous cell carcinoma. We describe a case of a large, locally invasive basosquamous carcinoma, an aggressive type of BCC, invading the left sternocleidomastoid muscle with near compression of the left internal jugular vein producing a severe anaemia secondary to ulceration and chronic blood loss. The patient was initially started on vismodegib monotherapy but failed to respond. He was then started on cemiplimab in addition to vismodegib. Improvement was noted after one cycle. After 21 cycles of cemiplimab, the left shoulder ulcerated lesion was completely re-epithelialised. He remains in complete remission after 31 cycles of cemiplimab in addition to vismodegib.<\/jats:p>","DOI":"10.1136\/bcr-2022-251273","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T06:25:15Z","timestamp":1689315915000},"page":"e251273","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib"],"prefix":"10.1136","volume":"16","author":[{"given":"Jonathan","family":"Pirruccello","sequence":"first","affiliation":[{"name":"Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-1639","authenticated-orcid":false,"given":"Muhammad Zubair","family":"Afzal","sequence":"additional","affiliation":[{"name":"Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Voudouri","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03750"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Shirai","sequence":"additional","affiliation":[{"name":"Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"2025082712502560000_16.7.e251273.1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjd.12394","article-title":"Dermoscopy of Basosquamous carcinoma","volume":"169","author":"Giacomel","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025082712502560000_16.7.e251273.2","first-page":"830","article-title":"Basosquamous carcinoma","volume":"29","author":"Bowman","year":"2003","journal-title":"Dermatol Surg"},{"key":"2025082712502560000_16.7.e251273.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113713"},{"key":"2025082712502560000_16.7.e251273.4","unstructured":"FDA APPROVES Cemiplimab-Rwlc for locally advanced and metastatic basal cell carcinoma. 2021. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-cemiplimab-rwlc-locally-advanced-and-metastatic-basal-cell-carcinoma"},{"key":"2025082712502560000_16.7.e251273.5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025082712502560000_16.7.e251273.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.036"},{"key":"2025082712502560000_16.7.e251273.7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.anndiagpath.2015.01.004","article-title":"Basal cell carcinoma vs Basaloid squamous cell carcinoma of the skin: an immunohistochemical reappraisal","volume":"19","author":"Webb","year":"2015","journal-title":"Ann Diagn Pathol"},{"key":"2025082712502560000_16.7.e251273.8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00403-020-02058-1","article-title":"Reappraising Basosquamous carcinoma: a summary of histologic features, diagnosis, and treatment","volume":"312","author":"Shukla","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"2025082712502560000_16.7.e251273.9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/ced.14804","article-title":"Lasting response after discontinuation of Cemiplimab in a patient with locally advanced basal cell carcinoma","volume":"46","author":"De Giorgi","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2025082712502560000_16.7.e251273.10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jamadermatol.2021.2206","article-title":"Complete remission of basal cell carcinoma following treatment with Cemiplimab after 2 years","volume":"157","author":"Dumann","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025082712502560000_16.7.e251273.11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4103\/ijdvl.IJDVL_647_18","article-title":"Complete response of a locally advanced Basosquamous carcinoma with Vismodegib treatment","volume":"85","author":"Sahuquillo-Torralba","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2025082712502560000_16.7.e251273.12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1684\/ejd.2018.3482","article-title":"Complete response of locally advanced Basosquamous carcinoma to Vismodegib in two patients","volume":"29","author":"Apalla","year":"2019","journal-title":"Eur J Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-251273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:50:33Z","timestamp":1756324233000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-251273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,14]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/bcr-2022-251273"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-251273","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}